Waters Corporation (WAT) 2024 10-K Earnings Analysis
Waters Corporation2024 Earnings Analysis
77/100
Waters Corporation entered FY2024 with a business model defined more by operating discipline than by financial engineering, and the filing for the period ended December 31, 2024 still points in that direction: $2.96B of revenue, $638M of net income, and $620M of free cash flow. LC-MS Platform, BD Biosciences Transaction, and LC-MS Standard remain the clearest way to understand where the economics come from and why margin durability looks different here than it would at a generic peer. The combination of 59.4% gross margin and 27.9% operating margin suggests LC-MS Platform was still pricing and executing well. What matters most from here is whether the existing economics can hold through the next turn in demand.
Filing analysis
Waters Corporation 2024 10-K Analysis
This page reads Waters Corporation's 2024 10-K annual report through the EarningsMoat framework: earnings quality, economic moat strength, capital allocation, and key risks. The current overall score is 77/100, or grade C.
WAT Earnings Quality
The earnings-quality module scores 80/100, with Gross Margin: 59.4%, Operating Margin: 27.9%. The core question is whether reported profit is backed by operating cash flow and recurring business economics. See the earnings quality analysis guide.
WAT Economic Moat Analysis
The moat-strength module scores 80/100, with LC-MS Standard: Pharma analytical, Validated-Method Lock-In: Regulatory inertia. The test is whether the advantage can protect returns after competitors react. Read the economic moat analysis guide.
WAT Free Cash Flow vs Net Income
CF/Net Income: 1.19x is the fastest read on whether accounting earnings turn into cash. The capital-allocation module scores 78/100. For the diagnostic, start with cash flow vs net income.
WAT Key Risks from the Annual Report
The risk module scores 70/100, with Pharma Capex Cycle: Funding sensitivity, China Pharma Spending: VBP/policy headwinds. The goal is to separate ordinary disclosure from risks that can change margins, cash flow, leverage, or the moat itself.
Is WAT a High Quality Earnings Stock?
Based on this 2024 filing, WAT passes the first screen for high-quality earnings: the overall grade is C, and the earnings-quality score is 80/100. This is a research screen, not investment advice.
Read the report first
Understand Waters Corporation first, then decide if it belongs on your watchlist
The WAT score, explanation, management facts, and filing sources are all here. When you want to follow more companies, review new-filing changes, or keep notes for the next review, keep more names in your watchlist.
Read the report first
Understand the company first. Keep up with every filing as your list grows.
A single report helps you judge one company. As your watchlist grows, review score, cash flow, moat, and risk changes together instead of repeating the same work.
Keep more names together
When your list grows, keep WAT with the rest of your names and review score, grade, and risk changes over time.
See how to track more namesAsk follow-up questions
Dig into cash conversion, moat evidence, capital allocation, and risk changes without rereading the full 10-K.
Ask a questionExport and revisit records
Save the WAT report as research notes you can revisit before the next filing.
Save research notesCore Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Earnings Quality
Gross Margin matters here because gross Margin matters here because gross Margin matters here because gross margin of 59.4% reflects the disclosed instrument and recurring revenue (consumables and service) mix.
A better way to read operating margin is to notice that a better way to read operating margin is to notice that a better way to read operating margin is to notice that the 27.9% operating margin reflects the disclosed instrument installed base economics — recurring-revenue contribution from consumables and service.
CF / Net Income is not just a statistic here; it shows that CF / Net Income is not just a statistic here; it shows that CF / Net Income is not just a statistic here; it shows that OCF of $762M is 1.19x net income of $638M — reflecting depreciation per the cash-flow reconciliation.
The earnings file is readable because LC-MS Platform keeps margins and cash pointing in the same direction: 59.4% gross margin, 27.9% operating margin, and 1.19x cash conversion. The mix around LC-MS Platform and BD Biosciences Transaction kept the economics intact even while end-market conditions stayed uneven. 27.9% operating margin and 4.8% capex intensity are a coherent pair once LC-MS Platform is put at the center of the business model. LC-MS Platform is still turning accounting profit into cash at a healthy rate, which makes the FY2024 result easier to trust.
Moat Strength
The practical value of lc-ms standard is that the practical value of lc-ms standard is that the practical value of lc-ms standard is that synapt platforms as described in the product line) systems are widely-deployed in pharma analytical labs per public industry communications.
Per SEC and company filings, validated-Method Lock-In helps explain why validated-Method Lock-In helps explain why validated-Method Lock-In helps explain why pharma-validated analytical methods using Waters instruments create regulatory-inertia switching cost (FDA / EMA-validated method change requires revalidation per public regulatory practice).
Read recurring service revenue as evidence that read recurring service revenue as evidence that read recurring service revenue as evidence that recurring revenue (chemistry consumables + service contracts) contributes approximately half of revenue mix as described in the revenue-decomposition.
A better way to frame the moat question is to start with LC-MS Platform and BD Biosciences Transaction. The picture gets stronger once LC-MS Standard and Validated-Method Lock-In are added, because they make the advantage broader than one single product cycle. The numbers back the qualitative case because LC-MS Platform still shows up in 34.9% ROE and solid cash generation at the same time. The conclusion is not invincibility; it is that the next rival still has to beat LC-MS Platform inside a real workflow advantage.
Capital Allocation
Free Cash Flow tells you that free Cash Flow tells you that free Cash Flow tells you that FCF of $620M (OCF $762M minus capex $142M) supports the disclosed share-repurchase program.
The reason to focus on share repurchase is that the reason to focus on share repurchase is that the reason to focus on share repurchase is that waters returns FCF principally through share repurchase as described in the buyback authorization.
Net Debt Position matters in capital allocation because net Debt Position matters in capital allocation because net Debt Position matters in capital allocation because long-term debt of $1.63B against $325M cash equals net debt of $1.31B as described in the capital-structure footnote.
The allocation question begins with $620M of free cash flow and with how much cash LC-MS Platform leaves behind, not with headline EPS. The low capex burden at 4.8% of revenue gives management more freedom over buybacks, dividends, M&A, or balance-sheet repair around LC-MS Platform. Cash at $325M does not erase debt at $1.63B, so the balance sheet still leans on a durable cash engine. Both the dividend and repurchases remain in play, so capital allocation around LC-MS Platform is balanced rather than one-dimensional.
Key Risks
Pharma Capex Cycle matters as a risk because pharma Capex Cycle matters as a risk because pharma Capex Cycle matters as a risk because waters' instrument-revenue tracks pharma and biotech R&D capital budget cycles as described in the customer-base communications (current biotech-funding environment has been challenging per public industry data).
What china pharma spending adds to the risk case is that what china pharma spending adds to the risk case is that what china pharma spending adds to the risk case is that china-pharma analytical-instrument spending has been pressured by VBP and anti corruption policy dynamics per public industry communications.
Wyatt and BD BS Integration is worth tracking because wyatt and BD BS Integration is worth tracking because wyatt and BD BS Integration is worth tracking because integration execution affects acquisition-driven revenue growth.
The filing points to a cluster of risks around Wyatt and BD BS Integration and execution pressure rather than one neat red flag. A modest miss around Wyatt and BD BS Integration can still show up in margins and cash faster than investors expect. The balance sheet adds its own watch item because goodwill is 28.5% of assets and keeps attention on LC-MS Platform-related follow-through. What matters most from here is whether the existing economics can hold through the next turn in demand.
Management
Ask about this section
Ask one question here. Keep digging when the issue needs more work.
This analysis is for educational purposes only and does not constitute investment advice.